Idiopathic pulmonary fibrosis: Treatment update

被引：18
作者：
O'Connell, Oisin J. [1 ]
Kennedy, Marcus P. [1 ]
Henry, Michael T. [1 ]
机构：
[1] Natl Univ Ireland Univ Coll Cork, Dept Resp Med, Cork, Ireland
来源：
ADVANCES IN THERAPY | 2011年 / 28卷 / 11期
关键词：
antifibrotic; idiopathic pulmonary fibrosis; patient management; treatment; PLACEBO-CONTROLLED TRIAL; ACID GASTROESOPHAGEAL-REFLUX; CELL LUNG-CANCER; INTERFERON GAMMA-1B; FACTOR EXPRESSION; PROGNOSTIC VALUE; HIGH PREVALENCE; DOUBLE-BLIND; PIRFENIDONE; HYPERTENSION;
D O I：
10.1007/s12325-011-0066-5
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.
引用
收藏
页码：986 / 999
页数：14
相关论文
共 62 条
[61]   A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis [J].
Ziesche, R ;
Hofbauer, E ;
Wittmann, K ;
Petkov, V ;
Block, LH .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (17) :1264-1269
[62]   A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis [J].
Zisman, David A. ;
Schwarz, Marvin ;
Anstrom, Kevin J. ;
Collard, Harold R. ;
Flaherty, Kevin R. ;
Hunninghake, Gary W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (07) :620-628
1234567